Neurocrine Biosciences, Inc. (NBIX)
169.13
+0.27
(+0.16%)
USD |
NASDAQ |
Nov 10, 16:00
168.40
-0.73
(-0.43%)
After-Hours: 20:00
Neurocrine Biosciences Cash from Operations (Annual) : 782.70M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 782.70M |
| December 31, 2024 | 595.40M |
| December 31, 2023 | 389.90M |
| December 31, 2022 | 339.40M |
| December 31, 2021 | 256.50M |
| December 31, 2020 | 228.50M |
| December 31, 2019 | 152.05M |
| December 31, 2018 | 101.36M |
| December 31, 2017 | -94.33M |
| December 31, 2016 | -106.18M |
| December 31, 2015 | -38.00M |
| December 31, 2014 | -47.14M |
| December 31, 2013 | -29.61M |
| December 31, 2012 | -35.29M |
| December 31, 2011 | -0.681M |
| Date | Value |
|---|---|
| December 31, 2010 | 49.94M |
| December 31, 2009 | -53.10M |
| December 31, 2008 | -74.17M |
| December 31, 2007 | -59.33M |
| December 31, 2006 | -99.33M |
| December 31, 2005 | -30.79M |
| December 31, 2004 | -99.99M |
| December 31, 2003 | 37.13M |
| December 31, 2002 | -79.36M |
| December 31, 2001 | -21.86M |
| December 31, 2000 | -18.64M |
| December 31, 1999 | -10.26M |
| December 31, 1998 | -10.70M |
| December 31, 1997 | 10.99M |
| December 31, 1996 | 6.682M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Amgen, Inc. | 9.958B |
| Halozyme Therapeutics, Inc. | 651.56M |
| BioCryst Pharmaceuticals, Inc. | 329.88M |
| Iovance Biotherapeutics, Inc. | -302.41M |
| Precigen, Inc. | -87.83M |